Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
DNTH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-3.78
vs -2.10
Q4.23
N/A
-0.71
vs -7.70
Q1.24
N/A
-0.54
vs NA
Q2.24
N/A
-0.51
vs -0.05
Q3.24
N/A
-0.74
vs -3.78
Q4.24
N/A
-0.81
vs -0.71
Q1.25
N/A
-0.82
vs -0.54
Q2.25
N/A
-0.88
vs -0.51
Q3.25
N/A
-0.88
vs -0.74
Q4.25
N/A
-0.85
vs -0.81
Sales Growth
YoY
Current
Estimates
Q3.23
-21%
924K vs 1.2M
Q4.23
-61%
457K vs 1.2M
Q1.24
+84%
874K vs 476K
Q2.24
+92%
1.9M vs 969K
Q3.24
+135%
2.2M vs 924K
Q4.24
+190%
1.3M vs 457K
Q1.25
+33%
1.2M vs 874K
Q2.25
-90%
193K vs 1.9M
Q3.25
-71%
640K vs 2.2M
Q4.25
-60%
530K vs 1.3M
Return on Equity
QoQ
Q1.23
-38%
-0.38
vs 0.23
Q2.23
-4%
-0.04
vs -0.38
Q3.23
-8%
-0.08
vs -0.04
Q4.23
-6%
-0.06
vs -0.08
Q1.24
-4%
-0.04
vs -0.06
Q2.24
-5%
-0.05
vs -0.04
Q3.24
-7%
-0.07
vs -0.05
Q4.24
-8%
-0.08
vs -0.07
Q1.25
-9%
-0.09
vs -0.08
Q2.25
-10%
-0.10
vs -0.09
Institutionnal Ownership
QoQ
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
31
31
vs NA
NA
Q4.23
38
38
vs 31
23%
Q1.24
76
76
vs 38
100%
Q2.24
74
74
vs 76
-3%
Q3.24
92
92
vs 74
24%
Q4.24
94
94
vs 92
2%
Q1.25
102
102
vs 94
9%
Q2.25
104
104
vs 102
2%
globenewswire.com
16 hours ago
globenewswire.com
22 hours ago
Quote Panel
Key Metrics
Forecast
1237%2026-Revenue
-304%2026-EPS
96%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
75.50(103.18%)
Number of analyst
2
Last analyst upgrade/downgrade
Oppenheimer
initialisePrevious: Not converted
2024-10-02
Now: Outperform
Cantor Fitzgerald
initialisePrevious: Not converted
2024-06-27
Now: Overweight
H.C. Wainwright
initialisePrevious: Not converted
2024-05-16
Now: Buy
Wedbush
initialisePrevious: Not converted
2023-11-22
Now: Outperform
Relative Strength
DNTH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
NASDAQ
Unprofitable
Unprofitable
-0.70 ( -1.85%)
Relative Strenght
93
Volume Buzz
82%
Earning Acce
No
Dist 52w H.
4%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How DNTH compares to sector?
DNTH
-12x